Clinical trial Recruiting at 1 site Observational Ages 18 and up

Registry for patients with chronic thromboembolic disease

Official title: Chronic Thromboembolic Disease: A Prospective Registry

Run by University of California, San Francisco · NCT05843500 · Data updated 2026-11-12

This study is collecting information from patients with chronic thromboembolic disease to see how different treatments affect their health and quality of life over time.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Locations1 site (San Francisco, California)
StatusRecruiting
StartedAugust 1, 2023
Main results expectedJuly 1, 2028
Study endsJuly 1, 2028
Registry record updatedJuly 14, 2026
Trial IDNCT05843500 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older diagnosed with chronic thromboembolic disease or chronic thromboembolic pulmonary hypertension.

Probably not a fit

Patients with pulmonary hypertension from causes other than chronic thromboembolic disease may not benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry aims to gather data on the natural history of patients diagnosed with chronic thromboembolic disease (CTD) and chronic thromboembolic pulmonary hypertension (CTEPH). It will assess long-term outcomes following various treatments, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy. Participants will be followed over time to evaluate their health outcomes and quality of life through chart reviews and health quality surveys.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into treatment effectiveness and improve management strategies for patients with chronic thromboembolic disease.

How similar studies have gone: Other studies have shown success in understanding chronic thromboembolic disease through registries, indicating that this approach is both valuable and tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients referred with CTED and/or CTEPH defined as:

  1. Mean pulmonary arterial pressure (mPAP) \> 20 mmHg at rest with pulmonary vascular resistance (PVR) \> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH)
  2. Radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram
  3. Post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension
* Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH
* Age ≥ 18 years

Exclusion Criteria:

* Main cause of PH other than World Health Organization (WHO) group 4 (CTEPH)
* Patient's refusal to participate in clinical research and/or receive intervention

Where it's running

  • University of California San Francisco
    San Francisco, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.